Cell Cryopreservation Companies | Corporate Milestones | Value Creation | Cross-border Expansion | Intellectual Property (IP) Portfolio Management | Competitive Performance Benchmarking

Cell Cryopreservation Market Trends and Companies Shares

The global cell cryopreservation market size is calculated at US$ 11.48 in 2024, grew to US$ 13.89 billion in 2025, and is projected to reach around US$ 77.52 billion by 2034. The market is expanding at a CAGR of 21.05% between 2024 and 2034.

Top companies in the cell cryopreservation include:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Sartorius AG
• PromoCell GmbH
• Lonza
• HiMedia Laboratories
• Creative Biolabs
• Corning Incorporated
• BioLife Solutions Inc.

Latest Announcements by Industry Leaders

In October 2024, the Board of Directors authorized the payment of a regular quarterly cash dividend to its shareholders of record as of the close of business on November 15, 2024, at an initial rate of $0.25 per share of common stock, according to a statement released by Cryo-Cell International, Inc. November 29, 2024, is the anticipated date of the dividend payment. The dividend policy will be regularly reviewed by the Board of Directors, taking into account the company's cash flows, profitability, and potential alternative uses and access to capital.

Recent Developments in the Cell Cryopreservation Market

• In September 2024, the novel aseptic micro-connector produced by CPC (Colder Products Company), a division of Dover, is designed to slot straight into the frozen cassettes used in the processing of cell and gene therapy (CGT). Cryopreservation, which involves freezing CGT biological materials at extremely low temperatures, reduces material loss of function that happens during product storage and transportation, which takes place prior to patient therapy delivery.
• In October 2024, according to David Sheehan, CEO of Nucleus Biologics, the introduction of NB-KUL DF ushers in a new era in the cryopreservation of cells employed for therapeutic purposes. This solution will remove negative effects for patients while lowering complexity and expense.

If you have any questions, please feel free to contact us at sales@towardshealthcare.com